172 related articles for article (PubMed ID: 23560740)
1. Etravirine for the treatment of HIV/AIDS.
Schrijvers R
Expert Opin Pharmacother; 2013 Jun; 14(8):1087-96. PubMed ID: 23560740
[TBL] [Abstract][Full Text] [Related]
2. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
[TBL] [Abstract][Full Text] [Related]
4. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
[TBL] [Abstract][Full Text] [Related]
5. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of etravirine.
Dickinson L; Khoo S; Back D
Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1575-85. PubMed ID: 21077784
[TBL] [Abstract][Full Text] [Related]
7. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Johnson LB; Saravolatz LD
Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
[TBL] [Abstract][Full Text] [Related]
8. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
9. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
[TBL] [Abstract][Full Text] [Related]
11. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Fulco PP; McNicholl IR
Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
[TBL] [Abstract][Full Text] [Related]
12. A review of the safety and tolerability profile of the next-generation NNRTI etravirine.
Grinsztejn B; Di Perri G; Towner W; Woodfall B; De Smedt G; Peeters M
AIDS Res Hum Retroviruses; 2010 Jul; 26(7):725-33. PubMed ID: 20624073
[TBL] [Abstract][Full Text] [Related]
13. [Etravirine in first-line therapy].
Garcés PA; Tena EV
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():12-20. PubMed ID: 20116623
[TBL] [Abstract][Full Text] [Related]
14. Etravirine.
Deeks ED; Keating GM
Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
[TBL] [Abstract][Full Text] [Related]
15. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
Jayaweera D; Dilanchian P
Expert Opin Pharmacother; 2012 Dec; 13(18):2601-12. PubMed ID: 23176566
[TBL] [Abstract][Full Text] [Related]
17. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Tudor-Williams G; Cahn P; Chokephaibulkit K; Fourie J; Karatzios C; Dincq S; Opsomer M; Kakuda TN; Nijs S; Tambuyzer L; Tomaka FL;
HIV Med; 2014 Oct; 15(9):513-24. PubMed ID: 24589294
[TBL] [Abstract][Full Text] [Related]
18. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.
Croxtall JD
Drugs; 2012 Apr; 72(6):847-69. PubMed ID: 22512366
[TBL] [Abstract][Full Text] [Related]
19. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
20. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
Adams J; Patel N; Mankaryous N; Tadros M; Miller CD
Ann Pharmacother; 2010 Jan; 44(1):157-65. PubMed ID: 19996323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
